Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JGOG3023: Bevacizumab Beyond Progression in Platinum-Resistant Recurrent Ovarian Cancer
jRCTs031180244Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Progression-free survival. Started Sep 2015; status: completed.
02
Drugs
bevacizumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)ovarian cancer
Beyond the preview
Go deeper on jRCTs031180244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180244.